目的 探讨红花逍遥片联合雌二醇片/雌二醇地屈孕酮片复合包装治疗围绝经期综合征的临床效果。方法 选取2016年7月—2019年6月新乡市中心医院收治的100例围绝经期综合征患者，使用随机数字表法将其随机分成与对照组和治疗组，每组各50例。对照组口服雌二醇片/雌二醇地屈孕酮片复合包装，1片/次，1次/d，以28 d为1个疗程，前14 d服用白色片，后14 d服用灰色片。治疗组在对照组基础上口服红花逍遥片，3片/次，3次/d。两组均连续治疗3个疗程。观察两组的临床疗效，比较两组改良Kupperman绝经指数（KMI）评分、绝经期生存质量量表（MENQOL）总分、血流变学指标[全血高、低切黏度（HBV和LBV）、红细胞沉降率（ESR）和纤维蛋白原（FIB）]及血清性激素[卵泡刺激素（FSH）、促黄体生成素（LH）和雌二醇（E₂）]、炎症因子[肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6]水平的变化情况。结果 治疗后，治疗组总有效率为96.0%，显著高于对照组84.0%（P<0.05）。与治疗前相比，两组治疗后改良KMI评分和MENQOL总分均显著降低（P<0.05），且与对照组治疗后相比，治疗组对以上评分的改善效果更显著（P<0.05）。两组治疗后HBV、LBV、ESR及FIB均显著低于本组治疗前（P<0.05）；治疗后，治疗组血流变学指标低于对照组（P<0.05）。治疗后，两组血清FSH、LH、TNF-α和IL-6水平均较本组治疗前显著下降，但血清E₂水平均显著升高（P<0.05）；且治疗后治疗组血清性激素和炎症因子水平改善更明显（P<0.05）。结论 红花逍遥片联合雌二醇片/雌二醇地屈孕酮片复合包装治疗围绝经期综合征患者效果确切，能减轻患者围绝经期相关症状、提高生命质量，并能显著改善机体血液流变学状态、调节生殖内分泌紊乱及下调相关炎症因子表达，值得临床推广应用。

Objective To investigate the clinical effect of Honghua Xiaoyao Tablets combined with Estradiol tablets/estradiol dydrogesterone Tablets Composite Packaging in treatment of perimenopausal syndrome.Methods A total of 100 patients with perimenopausal syndrome admitted to Xinxiang Central Hospital from July 2016 to June 2019 were selected and randomly divided into control group and treatment group by random number table method, with 50 cases in each group. Patients in the control group were po administered with Estradiol tablets/estradiol dydrogesterone Tablets Composite Packaging, 1 tablet/time, once daily, 28 days as a course of treatment, the first 14 days to take white tablets, and the last 14 days to take gray tablets. Patients in the treatment group were po administered with Honghua Xiaoyao Tablets on the basis of the control group, 3 tablets/time, 3 times daily. Both groups were treated for 3 courses continuously. The clinical efficacy of the two groups was observed. The modified Kupperman menopausal index (KMI) score, menopausal quality of life scale (MENQOL) total score, hemorheology indexes [whole blood high and low shear viscosity (HBV and LBV), erythrocyte sedimentation rate (ESR) before and after treatment in the two groups), and fibrinogen (FIB)] serum sex hormones [follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E₂)], and inflammatory factors [tumor necrosis factor (TNF)-α, interleukin (IL)-6] were observed.Results The total effective rate of the treatment group was 96.0%, which was significantly higher than that of the control group 84.0% (P<0.05). Compared with before treatment, the modified KMI score and MENQOL total score were significantly decreased in both groups after treatment (P<0.05), and the improvement of the above scores in the treatment group was more significant than that in the control group after treatment (P<0.05). After treatment, HBV, LBV, ESR and FIB in two groups were significantly lower than those before treatment (P<0.05). After treatment, the hemorheological indexes of treatment group were lower than those of control group (P<0.05). After treatment, serum FSH, LH, TNF-α and IL-6 levels in two groups were significantly decreased compared with before treatment, but serum E₂ level was significantly increased (P<0.05). After treatment, the serum levels of sex hormones and inflammatory factors in the treatment group were significantly improved (P<0.05).Conclusion Honghua Xiaoyao Tablets combined with Estradiol tablets/estradiol dydrogesterone Tablets Composite Packaging has exact effect in treatment of perimenopausal syndrome, and can reduce perimenopausal symptoms, improve the life quality, and can significantly improve the body state of blood rheology, and regulate reproductive endocrine disorders and cut the related inflammation factor expression, which is worthy of clinical popularization and application.

R984

新乡市科技攻关计划项目（GXGG18038）